S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in
NASDAQ:CRSP

CRISPR Therapeutics Stock Forecast, Price & News

$189.77
-8.52 (-4.30 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$189.63
Now: $189.77
$200.85
50-Day Range
$131.54
MA: $166.23
$210.04
52-Week Range
$32.30
Now: $189.77
$220.20
Volume2.14 million shs
Average Volume2.76 million shs
Market Capitalization$13.51 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
CRISPR Therapeutics logo

MarketRank

Overall MarketRank

1.33 out of 5 stars

Medical Sector

670th out of 1,928 stocks

Biological Products, Except Diagnostic Industry

88th out of 177 stocks

Analyst Opinion: 2.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRSP
CUSIPN/A
Phone41-41-561-3277
Employees304

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$289.59 million
Cash Flow$1.23 per share
Book Value$17.02 per share

Profitability

Net Income$66.86 million
Net Margins-273.10%

Miscellaneous

Market Cap$13.51 billion
Next Earnings Date2/10/2021 (Estimated)
OptionableOptionable
$189.77
-8.52 (-4.30 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

How has CRISPR Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

CRISPR Therapeutics' stock was trading at $43.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRSP stock has increased by 338.5% and is now trading at $189.77.
View which stocks have been most impacted by COVID-19
.

Is CRISPR Therapeutics a buy right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRISPR Therapeutics stock.
View analyst ratings for CRISPR Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than CRISPR Therapeutics?

Wall Street analysts have given CRISPR Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CRISPR Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as CRISPR Therapeutics' CEO?

1,428 employees have rated CRISPR Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among CRISPR Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is CRISPR Therapeutics' next earnings date?

CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 10th 2021.
View our earnings forecast for CRISPR Therapeutics
.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) posted its earnings results on Monday, November, 2nd. The company reported ($1.32) EPS for the quarter, missing the Zacks' consensus estimate of ($1.18) by $0.14. The firm had revenue of $0.15 million for the quarter, compared to analysts' expectations of $2.22 million. CRISPR Therapeutics had a negative net margin of 273.10% and a negative return on equity of 20.72%. CRISPR Therapeutics's revenue was down 99.9% on a year-over-year basis. During the same period in the prior year, the business earned $2.40 EPS.
View CRISPR Therapeutics' earnings history
.

What price target have analysts set for CRSP?

16 brokers have issued 12 month price targets for CRISPR Therapeutics' stock. Their forecasts range from $31.00 to $210.00. On average, they anticipate CRISPR Therapeutics' share price to reach $141.79 in the next twelve months. This suggests that the stock has a possible downside of 25.3%.
View analysts' price targets for CRISPR Therapeutics
or view Wall Street analyst' top-rated stocks.

Are investors shorting CRISPR Therapeutics?

CRISPR Therapeutics saw a drop in short interest in the month of December. As of December 31st, there was short interest totaling 3,610,000 shares, a drop of 16.2% from the December 15th total of 4,310,000 shares. Based on an average daily volume of 1,320,000 shares, the days-to-cover ratio is presently 2.7 days.
View CRISPR Therapeutics' Short Interest
.

Who are some of CRISPR Therapeutics' key competitors?

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

Who are CRISPR Therapeutics' key executives?

CRISPR Therapeutics' management team includes the following people:
  • Dr. Rodger Novak, Founder, Chairman & Pres (Age 53)
  • Dr. Samarth Kulkarni, CEO & Director (Age 41, Pay $994.55k)
  • Mr. Michael John Tomsicek, Chief Financial Officer (Age 54, Pay $632.72k)
  • Dr. Lawrence Otto Klein Ph.D., Chief Operating Officer (Age 38, Pay $579.23k)
  • Mr. James R Kasinger, Gen. Counsel & Sec. (Age 48, Pay $605.3k)
  • Dr. Tony W. Ho M.D., Exec. VP of R&D (Age 54, Pay $722.98k)
  • Mr. Shaun Foy, Founder
  • Dr. Emmanuelle Marie Charpentier, Co-Founder & Scientific Advisory Board Member
  • Dr. Craig C. Mello, Scientific Founder & Advisory Board Member
  • Dr. Chad Cowan, Scientific Founder

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Columbus Circle Investors (0.08%), Kestra Advisory Services LLC (0.02%), SevenBridge Financial Group LLC (0.01%), Triton Wealth Management PLLC (0.01%), Aevitas Wealth Management Inc. (0.01%) and Traynor Capital Management Inc. (0.00%). Company insiders that own CRISPR Therapeutics stock include Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni and Tony W Ho.
View institutional ownership trends for CRISPR Therapeutics
.

Which major investors are selling CRISPR Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Exchange Traded Concepts LLC, McGuire Investment Group LLC, Patriot Financial Group Insurance Agency LLC, Westside Investment Management Inc., and Webster Bank N. A.. Company insiders that have sold CRISPR Therapeutics company stock in the last year include Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, and Tony W Ho.
View insider buying and selling activity for CRISPR Therapeutics
or view top insider-selling stocks.

Which major investors are buying CRISPR Therapeutics stock?

CRSP stock was purchased by a variety of institutional investors in the last quarter, including Kestra Advisory Services LLC, SevenBridge Financial Group LLC, Triton Wealth Management PLLC, Aevitas Wealth Management Inc., Meridian Wealth Management LLC, Pacific Wealth Strategies Group Inc., Vivid Financial Management Inc., and First American Bank.
View insider buying and selling activity for CRISPR Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $189.77.

How big of a company is CRISPR Therapeutics?

CRISPR Therapeutics has a market capitalization of $13.51 billion and generates $289.59 million in revenue each year. The company earns $66.86 million in net income (profit) each year or $1.17 on an earnings per share basis. CRISPR Therapeutics employs 304 workers across the globe.

What is CRISPR Therapeutics' official website?

The official website for CRISPR Therapeutics is www.crisprtx.com.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.